百奥泰：BAT1308注射液联合BAT4706注射液及注射用BAT8008治疗晚期实体瘤获批临床试验

Core Viewpoint - The company Baiotai (688177.SH) has received approval from the National Medical Products Administration for its clinical trial application of BAT1308 injection combined with BAT4706 injection and BAT8008 injection for the treatment of advanced solid tumors [1] Group 1 - The company has recently announced the receipt of the clinical trial approval notice from the National Medical Products Administration [1] - The approved clinical trial involves the combination of BAT1308 injection and BAT4706 injection, along with BAT8008 injection, targeting advanced solid tumors [1]